中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 8
Aug.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(8): 1627-1631

Analysis of etiological composition and clinical characteristics in 960 cases of unexplained liver disease diagnosed by liver biopsy

DOI: 10.12449/JCH250823
  • 1.

    Department of Respiratory and Critical Care Medicine，Zhaoqing Hospital of The Third Affiliated Hospital of Sun Yat-Sen University，Zhaoqing，Guangdong 526000，China

  • 2.

    Department of Infectious Diseases，The Third Affiliated Hospital of Sun Yat-Sen University，Guangzhou 510630，China

Research funding:

Natural Science Foundation of Guangdong Province-General Program (2021A1515012617)

More Information
  • Corresponding author: JIE Yusheng， jieyusheng@163.com （ORCID： 0000-0003-3756-0653）
  • Received Date: 2025-01-11
  • Accepted Date: 2025-03-12
  • Published Date: 2025-08-25
    Abstract
  •   Objective  To investigate the composition ratios and trends of different etiologies after liver biopsy for patients with unexplained liver diseases.  Methods  A retrospective analysis was performed for the etiology of 960 patients with unexplained liver diseases who were hospitalized and underwent liver biopsy in The Third Affiliated Hospital of Sun Yat-Sen University from January 2011 to December 2020， and the etiologies were categorized by year and age group. The chi-square test was used for comparison of categorical data between multiple groups， and the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups.  Results  There was a tendency of increase in the overall composition ratio of unexplained liver diseases over the past decade. The leading diagnosis after liver biopsy was autoimmune liver disease （AILD） in 306 patients （31.9%）， followed by nonalcoholic fatty liver disease （NAFLD） in 95 patients （9.9%） and drug-induced liver disease （DILI） in 82 patients （8.5%）， and there were still 320 patients with undetermined causes （33.3%）. There were significant differences in sex ratio and median age distribution between the patients with different etiologies （sex ratio： χ2=155.36， P<0.001； median age distribution： H=182.48， P<0.001）. AILD had been the leading etiology in 2011‍ ‍—‍ ‍2020， and there was a tendency of reduction in the composition ratio of AILD （χ2=24.40， P<0.001）. NAFLD accounted for the highest proportion of 17.6% in the adolescent stage， while AILD accounted for the highest proportion of 17.8%， 47.3%， and 56.3%， respectively， in the young， middle-aged， and elderly stages.  Conclusion  There is a tendency of increase in the composition ratio of unexplained liver diseases in patients undergoing liver biopsy， with AILD being the main disease diagnosed after liver biopsy， followed by NAFLD and DILI， but one-third of the patients still have an unclear etiological diagnosis.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    YANG YF. Road map of diagnosis in patients with unknown causes[J]. J Pract Hepatol, 2018, 21( 1): 1- 3. DOI: 10.3969/j.issn.1672-5069.2018.01.001.

    杨永峰. 不明原因肝病诊断思路[J]. 实用肝脏病杂志, 2018, 21( 1): 1- 3. DOI: 10.3969/j.issn.1672-5069.2018.01.001.
    [2]
    CHOWDHURY AB, MEHTA KJ. Liver biopsy for assessment of chronic liver diseases: A synopsis[J]. Clin Exp Med, 2023, 23( 2): 273- 285. DOI: 10.1007/s10238-022-00799-z.
    [3]
    CAMPBELL MS, REDDY KR. Review article: The evolving role of liver biopsy[J]. Aliment Pharmacol Ther, 2004, 20( 3): 249- 259. DOI: 10.1111/j.1365-2036.2004.02071.x.
    [4]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update[J]. J Clin Hepatol, 2015, 31( 12): 1941- 1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31( 12): 1941- 1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
    [5]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: a 2022 update[J]. Infect Dis Info, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
    [7]
    TOH BH. Diagnostic autoantibodies for autoimmune liver diseases[J]. Clin Transl Immunology, 2017, 6( 5): e139. DOI: 10.1038/cti.2017.14.
    [8]
    LIM J, KIM HJ. Epidemiology of autoimmune liver disease in Korea: Evidence from a nationwide real-world database[J]. Orphanet J Rare Dis, 2024, 19( 1): 178. DOI: 10.1186/s13023-024-03086-0.
    [9]
    PUROHIT T, CAPPELL MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy[J]. World J Hepatol, 2015, 7( 7): 926- 941. DOI: 10.4254/wjh.v7.i7.926.
    [10]
    INVERNIZZI F, CILLA M, TRAPANI S, et al. Gender and autoimmune liver diseases: Relevant aspects in clinical practice[J]. J Pers Med, 2022, 12( 6): 925. DOI: 10.3390/jpm12060925.
    [11]
    HAN SK, BAIK SK, KIM MY. Non-alcoholic fatty liver disease: Definition and subtypes[J]. Clin Mol Hepatol, 2023, 29( suppl): S5- S16. DOI: 10.3350/cmh.2022.0424.
    [12]
    GOLDNER D, LAVINE JE. Nonalcoholic fatty liver disease in children: Unique considerations and challenges[J]. Gastroenterology, 2020, 158( 7): 1967- 1983. e 1. DOI: 10.1053/j.gastro.2020.01.048.
    [13]
    SHAUNAK M, BYRNE CD, DAVIS N, et al. Non-alcoholic fatty liver disease and childhood obesity[J]. Arch Dis Child, 2021, 106( 1): 3- 8. DOI: 10.1136/archdischild-2019-318063.
    [14]
    MANN JP, VALENTI L, SCORLETTI E, et al. Nonalcoholic fatty liver disease in children[J]. Semin Liver Dis, 2018, 38( 1): 1- 13. DOI: 10.1055/s-0038-1627456.
    [15]
    FERRAIOLI G, MAIOCCHI L, RACITI MV, et al. Detection of liver steatosis with a novel ultrasound-based technique: A pilot study using MRI-derived proton density fat fraction as the gold standard[J]. Clin Transl Gastroenterol, 2019, 10( 10): e00081. DOI: 10.14309/ctg.0000000000000081.
    [16]
    SHEN T, LIU YX, SHANG J, et al. Incidence and etiology of drug-induced liver injury in Mainland China[J]. Gastroenterology, 2019, 156( 8): 2230- 2241. e 11. DOI: 10.1053/j.gastro.2019.02.002.
    [17]
    FISHER K, VUPPALANCHI R, SAXENA R. Drug-induced liver injury[J]. Arch Pathol Lab Med, 2015, 139( 7): 876- 887. DOI: 10.5858/arpa.2014-0214-RA.
    [18]
    WANG YY, XIE P. Risk factors of liver injury in patients with hepatitis B virus infection and pulmonary tuberculosis and predictive model construction[J/OL]. Chin J Exp Clin Infect Dis(Electron Edition), 2023, 17( 4): 267- 273. DOI: 10.3877/cma.j.issn.1674-1358.2023.04.008.

    王迎迎, 谢平. 乙型肝炎病毒感染合并肺结核患者发生肝损伤的危险因素及预测模型构建[J/OL]. 中华实验和临床感染病杂志(电子版), 2023, 17( 4): 267- 273. DOI: 10.3877/cma.j.issn.1674-1358.2023.04.008.
    [19]
    HE Y, LI BL, LI H. Analysis of influencing factors on drug-induced liver injury induced by anti-tuberculosis therapy in patients with newly treated pulmonary tuberculosis combined with hepatitis B virus infection[J]. J Changchun Univ Chin Med, 2024, 40( 4): 450- 454. DOI: 10.13463/j.cnki.cczyy.2024.04.023.

    贺毅, 李榜龙, 李慧. 初治肺结核合并乙型肝炎病毒感染患者抗结核治疗诱发药物性肝损伤的影响因素分析[J]. 长春中医药大学学报, 2024, 40( 4): 450- 454. DOI: 10.13463/j.cnki.cczyy.2024.04.023.
    [20]
    ETTEL M, GONZALEZ GA, GERA S, et al. Frequency and pathological characteristics of drug-induced liver injury in a tertiary medical center[J]. Hum Pathol, 2017, 68: 92- 98. DOI: 10.1016/j.humpath.2017.08.029.
    [21]
    KHALIFA A, ROCKEY DC. The utility of liver biopsy in 2020[J]. Curr Opin Gastroenterol, 2020, 36( 3): 184- 191. DOI: 10.1097/mog.0000000000000621.
    [22]
    CHOWDHURY AB, MEHTA KJ. Liver biopsy for assessment of chronic liver diseases: A synopsis[J]. Clin Exp Med, 2023, 23( 2): 273- 285. DOI: 10.1007/s10238-022-00799-z.
    [23]
    SCHNEIDER AL, KÖHLER H, RÖTHLISBERGER B, et al. Sodium taurocholate co-transporting polypeptide deficiency[J]. Clin Res Hepatol Gastroenterol, 2022, 46( 3): 101824. DOI: 10.1016/j.clinre.2021.101824.
    [24]
    LIU ZX, ZHAO WH, CAO CX, et al. Pituitary stalk interruption syndrome and liver cirrhosis associated with diabetes and an inactivating KCNJ11 gene mutation: A case report and literature review[J]. Front Endocrinol(Lausanne), 2023, 14: 1297146. DOI: 10.3389/fendo.2023.1297146.
    [25]
    LIBERAL R, GRANT CR. Cirrhosis and autoimmune liver disease: Current understanding[J]. World J Hepatol, 2016, 8( 28): 1157- 1168. DOI: 10.4254/wjh.v8.i28.1157.
    [26]
    ZHENG YF, ZHANG XL, WENG YH, et al. Etiological spectrum and clinical features of patients with unexplained liver disease manifesting as isolated jaundice: An analysis of 91 cases[J]. J Clin Hepatol, 2023, 39( 5): 1105- 1109. DOI: 10.3969/j.issn.1001-5256.2023.05.016.

    郑玉凤, 张胥磊, 翁宇航, 等. 91例以单纯性黄疸为表现的不明原因肝病患者病因谱及临床特征分析[J]. 临床肝胆病杂志, 2023, 39( 5): 1105- 1109. DOI: 10.3969/j.issn.1001-5256.2023.05.016.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (318) PDF downloads(39) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return